The Department of Veterans Affairs National Acquisition Center awarded an Indefinite Delivery Contract (IDC) to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer, to provide orexin inhibitors. The single-award IDC has a ceiling value of $2,129,424.50 and covers a one-year base period from May 28, 2023 to May 27, 2024, with four one-year option periods.
The contract aims to establish an indefinite delivery vehicle for a class of sleep-regulating pharmaceuticals, ensuring availability to veteran patients through the VA's Pharmaceutical Prime Vendor Program. The original solicitation, RFP 36E79723R0004, was issued on or about December 14, 2022 with a tentative closing date of December 28, 2022. The procurement is unrestricted and utilizes NAICS code 325412. The estimated annual usage is 110,610 tablets of orexin inhibitors, including drugs such as daridorexant, lemborexant, or suvorexant, to be delivered through the contract.
Generated 12/18/24, 9:07 AM